Unterberg Capital’s ChemoCentryx, Inc. CCXI Stock Holding History

Unterberg Capital’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50,000	Closed	-$659K	–	24
2018 Q2	$659K	Hold	50,000	–	–	0.78%	22
2018 Q1	$680K	Sell	50,000 -50,000	-50%	-$516K	0.79%	27
2017 Q4	$595K	Buy	+100,000	New	+$686K	0.73%	28

Other funds holding CCXI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Unterberg Capital's CCXI Position: Q3 2018 in Review

Unterberg Capital sold out of ChemoCentryx, Inc. (CCXI) in Q3 2018, closing a stake of 50,000 shares — an estimated $659K sold.

Unterberg Capital first reported a position in CCXI in Q4 2017 and held it in 3 quarters. The position peaked at $680K in Q1 2018. 106 funds tracked by Wall St. Rank hold CCXI as of Q3 2018.

Unterberg Capital reported no remaining ChemoCentryx, Inc. position as of Q3 2018 after selling out during the quarter.
Unterberg Capital sold 50,000 ChemoCentryx, Inc. shares in Q3 2018, an estimated $659K.
Unterberg Capital first reported a position in ChemoCentryx, Inc. in Q4 2017 and held it in 3 quarters.
Unterberg Capital's ChemoCentryx, Inc. position peaked at $680K in Q1 2018.
106 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2018.

Based on Unterberg Capital's 13F filing for Q3 2018, filed 24 Oct 2018.